SCHEMBL2870913

SCHEMBL2870913

CSc1nc2c(-c3ccc(OC(F)(F)F)cc3Cl)nccn2c1N(CCC(=O)N1CCCC1)CC1CC1

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.32
PTGES O14684 1/20 0.31
CRHR1 P34998 3/20 0.31
BTK Q06187 1/20 0.31
DRD3 P35462 1/20 0.30
EPHX2 P34913 1/20 0.30
F10 P00742 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2869373 0.90 CRHR1 (0.30) CRHR1
SCHEMBL2865140 0.88 CRHR1 (0.36) FFAR4CRHR1
SCHEMBL2864090 0.87
SCHEMBL2865138 0.87 CRHR1 (0.34) FFAR4CRHR1
SCHEMBL2868176 0.86 CRHR1 (0.32) FFAR4PTGESCRHR1DRD3
SCHEMBL2869284 0.84 CRHR1 (0.33) CRHR1
SCHEMBL2869015 0.84 RUNX1 (0.35) CRHR1
SCHEMBL2874249 0.84 CRHR1 (0.32) CRHR1
SCHEMBL2864479 0.80 CRHR1 (0.32) CRHR1
SCHEMBL2871962 0.80 PIM1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772249-B2 Imidazo[1,2-b]pyridazine compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-10 US disclosed
US-20090181985-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-16 US disclosed
US-20060211696-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-09-21 US disclosed
US-7078405-B2 Imidazo[1,2-b]pyridazine compound EISAI CO., LTD. (JP) 2006-07-18 US disclosed
US-20040082781-A1 Bicyclic nitrogenous fused-ring compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-04-29 US disclosed
EP-1364952-A1 BICYCLIC NITROGENOUS FUSED-RING COMPOUND Eisai Co., Ltd. (JP) 2003-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211696-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND CRHR1, CRHR2, CRH FFAR4 351/4885PTGES 3688/4885CRHR1 1/4885
US-20090181985-A1 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND CRHR1, CRHR2, CRH FFAR4 351/4885PTGES 3688/4885CRHR1 1/4885
US-20040082781-A1 Bicyclic nitrogenous fused-ring compound CRHR1, CRH, CRHR2 FFAR4 313/4885PTGES 4159/4885CRHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.